AI Article Synopsis

  • * The study found that Aβ-injected mice had higher levels of proteins related to cell death (like caspases) compared to control mice, but these levels dropped in mice that consumed BL for 6 weeks.
  • * BL also seemed to lessen the abnormal activation of certain proteins in the brain that are involved in stress responses, suggesting its potential as a treatment for cognitive impairments tied to Aβ.

Article Abstract

Probiotics are functional microorganisms that exhibit various biological activities, such as allergic reactions, inflammation, and aging. The aim of this study is to evaluate the effects of CBT BL3 (BL) on the amyloid beta (Aβ)-mediated cognitive impairments. Oral administration of live BL to intracerebroventricularly Aβ-injected mice significantly attenuated short- and long-term memory loss estimated using the Y-maze and Morris water maze tests. We found that expression of apoptosis-related proteins such as caspase-9, caspase-3, and cleaved poly (ADP-ribose) polymerase was significantly elevated in the brain tissues of Aβ-injected mouse brains when compared to that of the control mouse group. Interestingly, these expression levels were significantly decreased in the brain tissue of mice fed BL for 6 wk. In addition, the abnormal over-phosphorylation of mitogen-activated protein kinases (MAPKs) such as ERK1/2, p38 MAPK, and JNK in the brain tissue of intracerebroventricularly Aβ-injected mice was significantly attenuated by oral administration of BL. Taken together, the results indicate that Aβ-induced cognitive impairment may be ameliorated by the oral administration of BL by controlling the activation of MAPKs/apoptosis in the brain. This study strongly suggests that BL can be developed as a functional probiotic to attenuate Aβ-mediated cognitive deficits.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11097010PMC
http://dx.doi.org/10.5851/kosfa.2024.e5DOI Listing

Publication Analysis

Top Keywords

oral administration
16
cognitive deficits
8
amyloid beta
8
mitogen-activated protein
8
protein kinases
8
aβ-mediated cognitive
8
intracerebroventricularly aβ-injected
8
aβ-injected mice
8
mice attenuated
8
brain tissue
8

Similar Publications

Use of isavuconazole in mucormycosis: a systematic review.

BMC Infect Dis

January 2025

Department of Microbiology Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura Sri Lanka, 50008, Sri Lanka.

Background: Mucormycosis is an opportunistic fungal infection which is associated with poor prognosis. Only a few antifungals are available in the arsenal against mucormycosis. The global guidelines for diagnosing and managing mucormycosis recommend high doses of liposomal amphotericin B (LAmB) as the first-line treatment.

View Article and Find Full Text PDF

Background: Rimegepant, a novel oral calcitonin gene-related peptide receptor antagonist, has been recently approved for the acute migraine treatment. While its efficacy was confirmed in randomized clinical trials, no data is available regarding real-life effectiveness and tolerability. GAINER, a prospective, multicentric study, aimed to evaluate rimegepant effectiveness and tolerability in the real-world setting.

View Article and Find Full Text PDF

Background: Dengue fever (DF) is a mosquito-borne viral infection that has recently become a burden worldwide, particularly in low-income countries, such as Yemen. There have been no epidemiological studies on DF in recent years in Yemen. Therefore, based on secondary data, this study aimed to shed light on the epidemiology of DF in Yemen between 2020 and 2024.

View Article and Find Full Text PDF

Homozygous MTAP deletion occurs in ~15% of cancers, making them vulnerable to decreases in the concentration of S-adenosylmethionine (SAM). AG-270/S095033 is an oral, potent, reversible inhibitor of methionine adenosyltransferase 2 A (MAT2A), the enzyme primarily responsible for the synthesis of SAM. We report results from the first-in-human, phase 1 trial of AG-270/S095033 as monotherapy in patients with advanced malignancies (ClinicalTrials.

View Article and Find Full Text PDF

Objective: Traditional initial treatment regimens for lupus nephritis (LN) used oral glucocorticoids (GC) in starting doses up to 1.0 mg/kg/day prednisone equivalent with or without a preceding intravenous methylprednisolone pulse. More recent management guidelines recommend lower starting oral GC doses following intravenous pulse therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!